Controlling Health Care Costs Paying for Prescription Drugs Around the World: Why Is the U.S. an Outlier? Issue Briefs / Oct 05, 2017
Controlling Health Care Costs The Case for Drug-Pricing Reform — The Cost of Inaction blog / May 26, 2021
Controlling Health Care Costs External Reference Pricing: The Drug-Pricing Reform America Needs? Issue Briefs / May 27, 2021
Controlling Health Care Costs How Federal Drug-Pricing Proposals Could Affect Medicaid blog / Aug 19, 2021
Controlling Health Care Costs Reducing Medicaid Prescription Drug Costs While Maintaining Beneficiary Access: MACPAC Recommendations for Accelerated-Approval Drugs blog / Aug 18, 2021
Controlling Health Care Costs Perverse Incentives: Why Brand-Name Drugs Can Cost Less Than Generics for Medicare Beneficiaries Journal Article / Jul 01, 2019
Controlling Health Care Costs States Are Using Drug Importation to Lower Costs and Provide Safe Access to Drugs Blog / Jun 27, 2019
Controlling Health Care Costs Two Ways to Make Medicines More Affordable to Women Podcast / Jun 14, 2019
Controlling Health Care Costs Pharmacy Benefit Managers and Their Role in Drug Spending Explainer / Apr 22, 2019
Improving Health Care Quality Pharmacy Benefit Managers: Practices, Controversies, and What Lies Ahead Issue Briefs / Mar 26, 2019
Controlling Health Care Costs Administration’s New Budget Proposals May Align with Bipartisan Congressional Action to Lower Drug Prices Blog / Mar 15, 2019
Controlling Health Care Costs The Drug Pricing Debate: Sizing Up Recent Actions and What May Come Next Blog / Mar 07, 2019
Controlling Health Care Costs Reference Pricing in Germany: Implications for U.S. Pharmaceutical Purchasing Issue Briefs / Feb 04, 2019
Controlling Health Care Costs Proposed Changes to Medicare Part D Would Benefit Drug Manufacturers More Than Beneficiaries Blog / Jan 02, 2019